SynteractHCR moves to expanded HQ in California after Amulet buyout

Comes after a new CEO and buyout deal this year

CRO SynteractHCR, bought by Amulet Capital Partners back in May and with a new CEO this summer, has seen another change-up as it moves its headquarters to larger digs.

The new facility in Carlsbad, San Diego County, sees it gain 38,000 square feet of space and has been designed with an “open concept to foster collaboration and creates a dynamic team environment, right in line with the company’s innovative business philosophy,” according to a statement from the company.

It also has offices in the Research Triangle Park area of North Carolina, the home of many top CROs, as well as 10 additional offices in Western, Central, and Eastern Europe.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

SynteractHCR’s CEO Steve Powell, who took the helm of the CRO back in July after leaving Exco Intouch, said: “This move comes just one year after we doubled our space in Research Triangle Park and ensures we remain an important employer within the innovative local biotech and life science communities in San Diego, RTP and across the globe.

“The new Carlsbad space accommodates team members across all our core service offerings and is an important focus of operations for our experienced, knowledgeable staff of clinical development professionals. We look forward to hosting project teams and clients in this invigorating new environment.”

SynteractHCR was founded in 1995 and is now a top 20 full‐service CRO. It was since 2008 majority-owned by Gryphon Investors, a middle-market private equity firm based in San Francisco, before being bought out this year.

The company provides outsourced support to pharmaceutical companies, from drug development to marketing.

It has since grown further through acquisitions, with one of the biggest coming in 2013 when it acquired Germany’s Harrison Clinical Research—rebranding itself as SynteractHCR and expanding its reach to 16 countries.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.